About David Kita

With 20+ years’ experience leading R&D in small molecule drug discovery, translational research, clinical trials, CMC, and computational platform & scientific tools development, David Kita, Ph.D. is a biotechnology and pharmaceutical industry visionary and a cofounder of Verseon.

David is transforming drug discovery by developing novel small molecule drugs for challenging therapeutic indications, designed by harnessing the power of state-of-the-art molecular modeling and high-throughput computing. He created Verseon’s core molecule-engineering platform and leads multiple drug programs, many in advanced preclinical or early clinical, and oversees a large interdisciplinary team in drug discovery, translational research, CMC, and Phase I trials. He contributed to AIM’s 2nd-largest 2015 biotech IPO—netting $92M funding for Verseon at a $430M valuation.

David is an SME in drug discovery, translational research, biomarker development, CMC, and clinical trials covering cardiovascular disease, ophthalmology, orphan diseases, oncology, and antivirals. He also has deep experience in project management, controlling costs, protecting IP, building R&D organizations, fundraising, and other challenges—while catalyzing development of novel therapeutic molecules and solving scientific problems in computational chemistry & pharmaceutical informatics.

David is adept in developing integrated, computational R&D SME platforms emphasizing advanced molecular modeling, structure-based drug design, MD simulations, computational chemistry, bioinformatics, and applied math.

David is the inventor on 23 US Patents, co-authored 11 publications & posters (see link below in the Featured Section) and earned a PhD in Theoretical Astrophysics at UW-Madison

His Signature Strengths:

Small Molecule Drug Discovery
Translational Research
Clinical Trial Design & Ops
Life Sciences R&D Management

Computational Chemistry
Pharmaceutical Informatics / Bioinformatics
Software & Algorithm Development
Scientific Problem-Solving